We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
-11.03%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
–
Cap. Flow
+$1.23B
Cap. Flow %
112.84%
Top 10 Hldgs %
95.05%
Holding
16
New
16
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$400M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$169M
3
GBIO
Generation Bio
GBIO
+$145M
4
DYN icon
Dyne Therapeutics
DYN
+$126M
5
REPL icon
Replimune Group
REPL
+$96M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$8.51B
$437M 40.09%
+6,875,698
New +$400M
DAWN
2
DELISTED
Day One Biopharmaceuticals
DAWN
$138M 12.69%
+8,201,638
New +$169M
DYN icon
3
Dyne Therapeutics
DYN
$4.7B
$106M 9.76%
+8,934,902
New +$126M
REPL icon
4
Replimune Group
REPL
$941M
$87M 7.99%
+3,209,627
New +$96M
IMA
5
ImageneBio Inc
IMA
$63M
$62.9M 5.78%
+418,182
New +$67.8M
GBIO
6
DELISTED
Generation Bio
GBIO
$58.6M 5.38%
+827,888
New +$145M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$47.2M 4.34%
+2,232,251
New +$49.5M
XLO icon
8
Xilio Therapeutics
XLO
$59.9M
$44.1M 4.06%
+197,096
New +$47M
JBIO
9
Jade Biosciences
JBIO
$1.2B
$36.6M 3.36%
+88,682
New +$44.9M
TECX
10
Tectonic Therapeutic
TECX
$529M
$17.4M 1.6%
+376,739
New +$21.6M
SPRO icon
11
Spero Therapeutics
SPRO
$67.7M
$16.5M 1.52%
+1,031,160
New +$16.4M
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.84B
$15.4M 1.41%
+217,284
New +$21.8M
IRON icon
13
Disc Medicine
IRON
$2.96B
$15.3M 1.4%
+175,146
New +$17.2M
FSTX
14
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.01M 0.28%
+599,524
New +$3.62M
COGT icon
15
Cogent Biosciences
COGT
$6.65B
$1.91M 0.18%
+222,976
New +$1.94M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.09B
$1.78M 0.16%
+90,072
New +$1.68M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for Atlas Venture Life Science Advisors, which disclosed 16 positions worth $1.09B. Its ten largest holdings account for 95% of the portfolio.

Its largest position is Kymera Therapeutics: 6,875,698 shares worth $437M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Atlas Venture Life Science Advisors's largest Q4 2021 buy was Kymera Therapeutics: 6,875,698 shares worth $437M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $1.09B portfolio in Q4 2021.
  • Atlas Venture Life Science Advisors disclosed 16 positions in Q4 2021, its first 13F filing on record.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2021, filed 16 May 2022.